Organisation paid for research Program year 2025 Source: CMS Open Payments

Sanford Research

Neither a doctor nor a teaching hospital

Research payments

$6,937,070

827 payments

Through program year 2025, Sanford Research is reported as receiving $6,937,070 in research payments, across 827 payments.

By program year

7 rows

Year	Kind	Amount	Payments
2025	Research	$2,028,163	182
2024	Research	$825,815	126
2023	Research	$912,115	61
2022	Research	$697,735	109
2021	Research	$975,233	119
2020	Research	$918,322	131
2019	Research	$579,686	99

Breakdown

Who paid Research payments · program years 2019–2025

E.R. Squibb & Sons, L.L.C. $1,159,962 25 payments
Abbott Laboratories $1,158,402 234 payments
Pfizer Inc. $841,148 90 payments
Amgen Inc. $687,904 13 payments
Endotronix, Inc. $590,758 4 payments
Edwards Lifesciences Corporation $396,063 33 payments
MicroVention, Inc. $332,455 30 payments
Merck Sharp & Dohme Corporation $311,314 11 payments
Genzyme Corporation $219,423 25 payments
Takeda Pharmaceuticals U.S.A., Inc. $175,962 35 payments

Studies the money was for Research payments · program years 2019–2025

A Phase 1 Study of Sgnb6a in Advanced Solid Tumors $670,582 19 payments
CLASP II TR Pivotal, Study No. 2019-07 $396,063 33 payments
Proactive-Hf $369,945 2 payments
Ph I II CTLA4-NF FIH Mono Nivo Combo in Adv. Solid Tmr & Post PD1 Mel NSCLC $348,666 2 payments
Phase I II FIH Monotherapy Nivo Combination $325,149 3 payments
A Randomized Phase 3, Double-Blind Study of Chemotherapy With or Without Pembrolizumab Followed by Maintenance With Olaparib or Placebo for the First-Line Treatment of BRCA non-mutated Advanced Epithelial Ovarian Cancer EOC $206,368 3 payments
Post-Market Surveillance Study to Evaluate the Long-Term Safety and Effectiveness of the Lvis Device (Lvis Pas) $186,880 5 payments
Hemodynamic-GUIDEd Management of Heart Failure $181,093 17 payments
A Phase 1 Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 509 in Subjects With Metastatic Castration-Resistant Prostate Cancer $173,096 2 payments
Hemodynamic Guided Monitoring in Heart Failure (HF) Trial (GUIDE-HF) $169,826 9 payments

What the money was spent on Research payments · program years 2019–2025

Patient care $191,669 11 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.